Evidence map›Paper›PMID 39964654›Full record

ArticleMolecular diversity2025

Discovery of the novel celastrol-based PROTACs for the treatment of non-small cell lung cancer.

Chunhui Ma, Fang Wang, Yiqing Wang, Fan Wu, Xuguang Zhang, Chuanhua Ding, Jifeng Zhao, Ying Ma, Wanzhong Li, Wenshan Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chunhui MaDepartment of Clinical Laboratory, Affiliated Hospital of Shandong Second Medical University, Weifang, 261041, Shandong Province, China.
Fang WangSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, China.
Yiqing WangSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, China.
Fan WuSchool of Medical Laboratory, Shandong Second Medical University, Weifang, 261053, Shandong Province, China.
Xuguang ZhangDepartment of Clinical Laboratory, Affiliated Hospital of Shandong Second Medical University, Weifang, 261041, Shandong Province, China.
Chuanhua DingShandong Key Laboratory of Medicine and Health (Clinical Applied Pharmacology), Department of Pharmacy, Affiliated Hospital of Shandong Second Medical University, Weifang, 261041, Shandong Province, China.
Jifeng ZhaoShandong Key Laboratory of Medicine and Health (Clinical Applied Pharmacology), Department of Pharmacy, Affiliated Hospital of Shandong Second Medical University, Weifang, 261041, Shandong Province, China.
Ying MaSchool of Pharmacy, Tianjin Medical University, Tianjin, 300070, China.
Wanzhong LiSchool of Pharmacy, Shandong Second Medical University, Weifang, 261053, Shandong Province, China. liwz@sdsmu.edu.cn.
Wenshan LiuShandong Key Laboratory of Medicine and Health (Clinical Applied Pharmacology), Department of Pharmacy, Affiliated Hospital of Shandong Second Medical University, Weifang, 261041, Shandong Province, China. liuwenshan@sdsmu.edu.cn.

Funding

Natural Science Foundation of Shandong Province ZR2021QH311, ZR2022LSW016the Key R&D Program of Shandong Province 2024CXPT102
6 · The paper itself

Abstract

Lung cancer is the world's top ranked cancer, with non-small cell lung cancer accounting for over 80% of lung cancer, so it is an urgent need to find new treatment strategies for non-small cell lung cancer. Celastrol is one of the effective active ingredients in the plant Tripterygium wilfordii Hook. f., and research has found that celastrol has an inhibitory effect on non-small cell lung cancer. However, the significant toxic side effect of celastrol limits its clinical application. In this study, 9 novel celastrol derivatives were developed using PROTAC technology. Cell viability testing displayed that some compounds exhibited higher antiproliferative activity in cancer cells, and had lower toxicity to normal cells. Among them, compound MX-108 (11c) showed a high inhibitory activity with an IC

Indexed as

Antineoplastic AgentsCarcinoma, Non-Small-Cell LungDrug DiscoveryLung NeoplasmsTriterpenesAnimalsApoptosisCell Line, TumorCell ProliferationCell SurvivalHumansMiceMolecular Docking SimulationPentacyclic TriterpenesProteolysis Targeting ChimeraXenograft Model Antitumor AssaysAntineoplastic AgentscelastrolPentacyclic TriterpenesProteolysis Targeting ChimeraTriterpenesAnticancer activityCelastrolMolecular dockingPROTACQuantitative proteomics

Identifiers

PMID39964654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.